Lilly’s acquisition of Adverum, a company specializing in gene therapy for age-related macular degeneration, comes at a time when the gene therapy sector is facing significant headwinds. The upfront offer from Lilly is notably below Adverum’s recent closing share price, reflecting the current market skepticism surrounding gene therapies and their commercial viability.
This deal underscores the shifting landscape in the biotech industry, particularly as companies reassess their portfolios in light of regulatory hurdles and market performance. With Adverum’s gene therapy struggling to gain traction, Lilly’s decision to acquire the company may signal a strategic pivot towards bolstering its own ophthalmology pipeline, even as it navigates the complexities of integrating a troubled asset.
The implications of this acquisition could resonate throughout the pharmaceutical sector, prompting other companies to reevaluate their investments in gene therapies and consider similar consolidation strategies in response to evolving market dynamics.
Use the database as your supply chain compass →
